Pregledni rad
https://doi.org/10.20471/LO.2021.49.02-03.16
Adjuvant treatments in melanoma
Luka Simetić
orcid.org/0000-0003-2328-167X
; Medical Oncology Department, University Hospital Center Zagreb, Zagreb, Croatia
Krešimir Blažević
; Medical Oncology Department, University Hospital Center Zagreb, Zagreb, Croatia
Davorin Herceg
; Medical Oncology Department, University Hospital Center Zagreb, Zagreb, Croatia
Sažetak
For decades, interferon-alpha (IFN-α) has been the only option in the adjuvant treatment of high-risk melanoma. Despite numerous clinical trials and meta-analyzes, IFN-α is not yet a gold standard. It indeed showed benefit in progressionfree survival (PFS) and to a lesser extent in overall survival (OS) but at the cost of high toxicity.
The emergence of new, revolutionary therapies in the treatment of metastatic melanoma, like immunotherapy (checkpoint inhibitors - CTLA4 and PD1 inhibitors) and targeted therapies (BRAF and MEK inhibitors), led to considering their potential effect in adjuvant/preventive use.
A number of phase II and phase III trials analyzed the adjuvant application of targeted therapies and immunotherapies in completely resected stage III melanoma (IIIA, IIIB, IIIC) and stage IV melanoma (PD1 inhibitor nivolumab). They showed a clear benefit in relapse-free survival (RFS) and overall survival (OS). This led to a change in guidelines for adjuvant treatment of melanoma and approval of immunotherapy and targeted therapy by the FDA (Food and Drug Administration) and EMA (European medicines agency) in the indications mentioned above.
Further trials are underway in other high-risk stages (like IIC) and in neoadjuvant treatment of stage III melanoma.
Ključne riječi
melanoma; adjuvant therapies; BRAF and MEK; immunotherapy
Hrčak ID:
267959
URI
Datum izdavanja:
22.12.2021.
Posjeta: 1.165 *